APA (7th ed.) Citation

Briatico, D., Safa, N., Flageole, H., Khan, S., Pernica, J., Eltorki, M., . . . Livingston, M. H. (2025). Assessing the Longitudinal outcomes of Piperacillin/tazobactam versus ceftriAxone and metronidazole for Children with perforated Appendicitis (ALPACA): A protocol for a pilot randomized controlled trial. PLoS ONE, 20(11), 1. https://doi.org/10.1371/journal.pone.0335991

Chicago Style (17th ed.) Citation

Briatico, Daniel, Nadia Safa, Helene Flageole, Sarah Khan, Jeffrey Pernica, Mohamed Eltorki, Eyal Cohen, and Michael H. Livingston. "Assessing the Longitudinal Outcomes of Piperacillin/tazobactam Versus CeftriAxone and Metronidazole for Children with Perforated Appendicitis (ALPACA): A Protocol for a Pilot Randomized Controlled Trial." PLoS ONE 20, no. 11 (2025): 1. https://doi.org/10.1371/journal.pone.0335991.

MLA (9th ed.) Citation

Briatico, Daniel, et al. "Assessing the Longitudinal Outcomes of Piperacillin/tazobactam Versus CeftriAxone and Metronidazole for Children with Perforated Appendicitis (ALPACA): A Protocol for a Pilot Randomized Controlled Trial." PLoS ONE, vol. 20, no. 11, 2025, p. 1, https://doi.org/10.1371/journal.pone.0335991.